The ups and downs of pharmacopoieal harmonization
This article was originally published in SRA
Executive Summary
As drug regulation becomes more global in nature, international trade continues to expand, and drug substances are increasingly manufactured using biotechnology techniques, the European Pharmacopoeia Commission is taking steps to develop more harmonized international quality standards, and is also extending its reach to encompass the quality of finished products rather than just pharmaceutical substances.
You may also be interested in...
Coronavirus Notebook: EU Publishes CureVac Vaccine Contract, AZ and Pfizer Under Attack Over Supply Cuts
The European Ombudsman has opened an inquiry regarding the disclosure of vaccine contracts with other companies, and the European Commission is planning a “sharing mechanism” for vaccines bought by EU member states.
Pfizer/BioNTech’s COVID-19 Vaccine First To Be Approved In Australia
Australia will begin its coronavirus vaccination program with Comirnaty. The Oxford University/AstraZeneca vaccine is expected to be the next to receive approval.
Hungary Breaks Ranks With EU & Authorizes Use Of AstraZeneca Vaccine
Hungary is going its own way when it comes to coronavirus vaccines, but its decision to allow the emergency use of the Oxford University/AstraZeneca vaccine may be only a symbolic expression of the government’s growing impatience with the EU.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: